| Wiki Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Investing Mistakes Series: Mistake #3 Investing in Mutual Funds |
|
Wiki Articles - Investing Mistakes Series: Mistake #3 Investing in Mutual Funds
Many people believe that mutual funds are simply the best way to invest for
the long term. That's what all the advertisements say, right? They are
diversified, relatively safe, and have professional management. For some people,
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product investing in mutual funds makes a lot of sense. People who should invest in
mutual funds know that the stock market is a great way to create lasting wealth,
but they don't want to make the effort to learn to invest correctly.
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in These people are not "too dumb", or "don't have time", or whatever excuse
they make. There is nothing wrong with someone like this, they just make it a
lot more difficult to create wealth for themselves. Investing is a continual lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
learning process. There is no magic formula or special degree required to be a
great investor. The only requirement is desire. Anyone can have that. For those
who don't want to make the effort to understand how the market works here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe , hand your
money to a pro. They will charge you outrageous fees, but at least you might be
able to sleep at night. Fees The main reason you want to avoid mutual funds, if you choose to make the effort, is fees. "Manag d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ement fees" and "loads" will rob you of potential
returns. Here's how: Without Mutual Funds Mary buys 100 shares of XYZ company. She pays her broker $10 to execute the trade. The shares were at $10 per share whe ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc n she bought the company. Her total
investment was $1000. She owns the stock for 5 years and it goes to $50 per
share. Her investment is now worth $5000 and she has a profit of $4000. Mary
decides to sell her shares. She pays h easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi er broker another $10 for the trade. Total Costs $20. Total account value after 5 years $4980. With Mutual Funds Joe buys shares of a mutual fund at $10 per share. He pays $10 to execute the trade. The mutua nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically l fund management fee is 1.5% per year. At the end of the first
year, the fund has gone from $10 to $20 per share. Joe pays $30 ($2000 new
account value x 1.5% management fees) Not only has he paid a fee, but that $30
he paid h and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ as no opportunity to compound. Instead of being worth $2000, Joe's
mutual fund is now worth $1970. If you use that math for the remaining 4 years,
Joe's account value ends up at $4617. He paid $194.63 in fees and lost an
additi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi onal $188.37 in potential returns. Oh yeah, he also paid another $10 to
sell. Total Costs $214.63. Lost Returns $188.37. Total account value after 5
years $4607. If you take that scenario and stretch it out to 10 years, t ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a he results are
even more dramatic. Why? Because as Joe's account grows in value, the fund takes
more and more in fees! The management fee percentage does not change. Management
is taking the same size piece of a larger pie. How dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod do you think they pay for all
the advertising? Mary will only pay the fees to execute the trades. Performance Most mutual funds fail to beat the market in a given year. In fact, 75% of actively managed funds fail to bea cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin t the market in a given year. This means that
75% of the time, you would get better returns by investing in a passively
managed index fund than investing in an actively managed mutual fund. As an
individual investor, you can be tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen at the market in most years. If you don't, at
least you aren't paying huge fees to someone on top of not beating the market. It's Not Their Fault Why do mutual fund managers lag the market most years? Because of the nature t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
of their job. They have to make most of the investment mistakes you aren't
supposed to make. They have a compressed time frame for their fund to perform.
They can advertise all they want, the bottom line is that performance at ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust tracts
more money and more fees for the fund. If the fund manager was buying stocks
when they are truly cheap and telling the fund holders to be patient, they would
pull their money out. The fund would then lose money and the m y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products anager would lose
his or her job. Wall Street professionals in general have so many pressures around them that it is difficult to ever be a great performer. Is it any wonder that Warren Buffett, the greatest investor who ever . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de lived is based in Omaha, Nebraska? Next
time read about all those analysts who make stocks move with their
recommendations and how you can profit from it. If you want to pay huge fees for poor performance, then mutual funds are elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip your
best bet. If you want to beat the market and not pay anyone else to do it, make
the effort to learn and invest for yourself. Good information is out there you
just need to find it. Check out the links below for more info. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Warning: Don't Cut Prices If You Want To Stay In Business Wait, Before You Fire up that Keyword Tool! One Way Links - Good Tips To Get Them
|